Jiangsu Aidea Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Jiangsu Aidea Pharmaceutical Co Ltd working capital to net assets ratio. Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Working Capital to Net Assets ratio of 39.6% as of June 2026. Working capital of CN¥385.42 Million (current assets of CN¥1.00 Billion minus current liabilities of CN¥616.05 Million) is measured against net assets of CN¥974.37 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
Working capital to net assets ratio of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 39.6%, reflecting working capital of CN¥385.42 Million against net assets of CN¥974.37 Million CNY. See how many days can Jiangsu Aidea Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Jiangsu Aidea Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2016–2025)
Jiangsu Aidea Pharmaceutical Co Ltd working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Jiangsu Aidea Pharmaceutical Co Ltd balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 21.4% | CN¥229.53 Million | CN¥1.07 Billion | CN¥938.74 Million | CN¥709.21 Million | ▼ -1.7 pp |
| 2024 | 23.0% | CN¥245.87 Million | CN¥1.07 Billion | CN¥894.93 Million | CN¥649.06 Million | ▼ -10.8 pp |
| 2023 | 33.8% | CN¥380.81 Million | CN¥1.13 Billion | CN¥872.38 Million | CN¥491.57 Million | ▼ -5.4 pp |
| 2022 | 39.3% | CN¥470.78 Million | CN¥1.20 Billion | CN¥802.46 Million | CN¥331.68 Million | ▼ -16.8 pp |
| 2021 | 56.1% | CN¥734.39 Million | CN¥1.31 Billion | CN¥826.93 Million | CN¥92.54 Million | ▼ -12.6 pp |
| 2020 | 68.7% | CN¥933.72 Million | CN¥1.36 Billion | CN¥1.01 Billion | CN¥73.00 Million | ▲ +40.1 pp |
| 2019 | 28.6% | CN¥158.99 Million | CN¥556.24 Million | CN¥368.11 Million | CN¥209.13 Million | ▲ +2.7 pp |
| 2018 | 25.9% | CN¥135.25 Million | CN¥522.71 Million | CN¥310.36 Million | CN¥175.11 Million | ▼ -7.5 pp |
| 2017 | 33.4% | CN¥171.66 Million | CN¥514.09 Million | CN¥305.07 Million | CN¥133.42 Million | ▲ +21.0 pp |
| 2016 | 12.3% | CN¥37.09 Million | CN¥300.40 Million | CN¥167.05 Million | CN¥129.96 Million | — |